Zebra Medical offers affordable access to deep-learning, image-analysis tools

This is the latest in Zebra Medical's quest to meet the growing demand for radiology services.

Zebra Medical Vision is on a mission to bridge the gap between supply and demand for radiology. To that end, the company is rolling out a new offering that includes all of its image analytics algorithms to healthcare providers for a flat rate per scan.

“With this new model, we hope to facilitate adoption globally, especially in countries where access to radiology is difficult,” said Zebra CEO Elad Benjamin, in a statement. “We are making a commitment to provide our current tools, and all future ones, for a flat $1 USD per scan. By doing so we believe that a true difference can be made in the provision of radiology services worldwide.”

Zebra’s artificial intelligence-powered image analysis system is already in use at more than 50 hospitals worldwide. In addition to targeting hospitals in the U.S. and Europe, Zebra recently partnered with India’s Teleradiology Solutions to bring its platform to another 20 countries in Asia and Africa.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: FierceMedicalDevices’ 2016 Fierce 15Zebra Medical Vision

The new offering, AI1, offers all of Zebra’s current and future image analysis algorithms that detect various findings in imaging. These include the detection of liver, lung, cardiovascular and bone disease. And the Shefayim, Israel-based company continues to work to add new algorithms, including those for breast cancer, lung cancer, brain trauma, hypertension, according to the statement.

The company trains its algorithms on an anonymized database of medical images and clinical data so they can detect certain markers in imaging. For example, the fatty liver algorithm screens for the condition by calculating the average density of the liver using CT scans of the chest and abdomen.

Suggested Articles

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.